

# George Bertσίας

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/143016/publications.pdf>

Version: 2024-02-01

221  
papers

13,241  
citations

47006

47  
h-index

24258

110  
g-index

228  
all docs

228  
docs citations

228  
times ranked

11566  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus"™ by Batu<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e145-e145.	0.9	3
2	Response to: Correspondence on "Update on the diagnosis and management of systemic lupus erythematosus" by Zhou<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e192-e192.	0.9	0
3	First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist. American Journal of Medicine, 2022, 135, 244-253.e3.	1.5	6
4	Changes in resting-state functional connectivity in neuropsychiatric lupus: A dynamic approach based on recurrence quantification analysis. Biomedical Signal Processing and Control, 2022, 72, 103285.	5.7	6
5	Treatment of lupus: more options after a long wait. Annals of the Rheumatic Diseases, 2022, 81, 753-756.	0.9	5
6	The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus. Lupus, 2022, , 096120332210745.	1.6	8
7	Converging evidence of impaired brain function in systemic lupus erythematosus: changes in perfusion dynamics and intrinsic functional connectivity. Neuroradiology, 2022, 64, 1593-1604.	2.2	4
8	Deciphering the Molecular Mechanism of Flares in Patients with Systemic Lupus Erythematosus through Single-Cell Transcriptome Analysis of the Peripheral Blood. Mediterranean Journal of Rheumatology, 2022, 33, 94.	0.8	0
9	Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
10	Lupus Nephritis: Improving Treatment Options. Drugs, 2022, 82, 735-748.	10.9	10
11	Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs. Frontiers in Immunology, 2022, 13, .	4.8	10
12	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	3.9	17
13	Recommendations for Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2022, 48, 617-636.	1.9	8
14	Cytotoxic drug treatment. , 2021, , 611-620.		0
15	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome <i>vs</i> rheumatoid arthritis: a multicenter, case-control study. Rheumatology, 2021, 60, 170-178.	1.9	24
16	Update in the diagnosis and management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 14-25.	0.9	312
17	Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort. Rheumatology, 2021, 60, 4166-4174.	1.9	6
18	Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 758-766.	0.9	50

#	ARTICLE	IF	CITATIONS
19	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
20	High Comorbidity Burden in Patients with SLE: Data from the Community-Based Lupus Registry of Crete. <i>Journal of Clinical Medicine</i> , 2021, 10, 998.	2.4	26
21	Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 317-329.	3.0	10
22	Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state functional MRI study. <i>Lupus Science and Medicine</i> , 2021, 8, e000473.	2.7	9
23	Relevant domains and outcome measurement instruments in neuropsychiatric systemic lupus erythematosus: a systematic literature review. <i>Rheumatology</i> , 2021, 61, 8-23.	1.9	9
24	POS0370â€¦TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 415-415.	0.9	0
25	POS0757â€¦SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DIAGNOSED DURING HOSPITALIZATION: CLINICAL PHENOTYPE AND PERFORMANCE OF THE SLE RISK PROBABILITY INDEX (SLRPI). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 631-631.	0.9	1
26	POS0759â€¦THE JOURNEY OF PATIENTS FROM FIRST SYMPTOMS TO DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): AN OBSERVATIONAL STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 632.2-633.	0.9	1
27	OP0019â€¦DEFINING SYSTEMIC LUPUS ERYTHEMATOSUS MOLECULAR TAXONOMY THROUGH DATA-DRIVEN RESTRATIFICATION AND IDENTIFICATION OF CLUSTER-TAILORED DRUGS FOR A PERSONALIZED MEDICINE APPROACH. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 11.1-11.	0.9	0
28	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.9	9
29	Extensive Changes in Transcription Dynamics Reflected on Alternative Splicing Events in Systemic Lupus Erythematosus Patients. <i>Genes</i> , 2021, 12, 1260.	2.4	5
30	NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-Î± production in patients with SLE. <i>JCI Insight</i> , 2021, 6, .	5.0	28
31	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , 2021, 8, e000542.	2.7	24
32	Epione application: An integrated webâ€¦toolkit of clinical genomics and personalized medicine in systemic lupus erythematosus. <i>International Journal of Molecular Medicine</i> , 2021, 49, .	4.0	3
33	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
34	Screening for cognitive impairment in systemic lupus erythematosus: Application of the Montreal Cognitive Assessment (MoCA) in a Greek patient sample. <i>Lupus</i> , 2021, 30, 2237-2247.	1.6	5
35	Dialogue: High-throughput studies in rheumatology: time for unsupervised clustering?. <i>Lupus Science and Medicine</i> , 2021, 8, e000643.	2.7	0
36	Hydroxychloroquine dosing in systemic lupus erythematosus: response to â€¦Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis<i> et alâ€™TM</i> by Costedoat-Chalumeau<i> et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e91-e91.	0.9	11

#	ARTICLE	IF	CITATIONS
37	Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to 2019 update of the EULAR recommendations for the management of SLE: don't forget chloroquine by Figueroa-Parra et al. Annals of the Rheumatic Diseases, 2020, 79, e115-e115.	0.9	1
38	Response to: Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine by Michaud et al. Annals of the Rheumatic Diseases, 2020, 79, e134-e134.	0.9	1
39	Response to: Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Rua-Figueroa and Erasquin. Annals of the Rheumatic Diseases, 2020, 79, e132-e132.	0.9	1
40	Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 242-253.	0.9	44
41	Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. Arthritis Research and Therapy, 2020, 22, 226.	3.5	9
42	Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus. Scientific Reports, 2020, 10, 16648.	3.3	8
43	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. Arthritis Research and Therapy, 2020, 22, 278.	3.5	7
44	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology, 2020, 59, v69-v81.	1.9	69
45	Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open, 2020, 6, e001263.	3.8	39
46	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). RMD Open, 2020, 6, e001192.	3.8	20
47	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
48	P0359CROSS-TISSUE AND MURINE-HUMAN COMPARATIVE TRANSCRIPTOME ANALYSES IDENTIFY TARGETABLE GENES FOR HUMAN SYSTEMIC LUPUS ERYTHEMATOUS AND LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
49	Response to: Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations by Orsolini et al. Annals of the Rheumatic Diseases, 2020, 79, e151-e151.	0.9	1
50	11...Remission and low disease activity: the new targets for treatment. , 2020, , .		0
51	Quantitative Identification of Functional Connectivity Disturbances in Neuropsychiatric Lupus Based on Resting-State fMRI: A Robust Machine Learning Approach. Brain Sciences, 2020, 10, 777.	2.3	18
52	An Update on the Diagnosis and Management of Lupus Nephritis. Current Rheumatology Reports, 2020, 22, 30.	4.7	21
53	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases, 2020, 79, 713-723.	0.9	463
54	Update on the cellular and molecular aspects of lupus nephritis. Clinical Immunology, 2020, 216, 108445.	3.2	28

#	ARTICLE	IF	CITATIONS
55	Simultaneous presentation of Lupus Erythematosus in a mother and a sibling pair. Australasian Journal of Dermatology, 2020, 61, e434-e435.	0.7	0
56	Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or "blood-dominant" lupus?. Annals of the Rheumatic Diseases, 2020, 79, 683-684.	0.9	14
57	In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Annals of the Rheumatic Diseases, 2020, 79, 232-241.	0.9	71
58	Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. Current Vascular Pharmacology, 2020, 18, 549-565.	1.7	61
59	Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors. Mediterranean Journal of Rheumatology, 2020, 31, 105.	0.8	13
60	Response to: "Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus" by Wuet al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217804.	0.9	0
61	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759
62	Immunometabolism: an overview and therapeutic prospects in autoimmune diseases. Immunotherapy, 2019, 11, 813-829.	2.0	53
63	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
64	Suspected systemic rheumatic diseases in patients presenting with cytopenias. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101425.	3.3	5
65	Regional cerebral perfusion correlates with anxiety in neuropsychiatric SLE: evidence for a mechanism distinct from depression. Lupus, 2019, 28, 1678-1689.	1.6	17
66	Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Annals of the Rheumatic Diseases, 2019, 78, 1079-1089.	0.9	109
67	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.9	1,265
68	Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus. Frontiers in Medicine, 2019, 6, 52.	2.6	5
69	Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Science and Medicine, 2019, 6, e000310.	2.7	40
70	THU0299"..."PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEH"ET"MS SYNDROME: A MULTICENTER STUDY. , 2019, , .		0
71	FRI0225"..."THE EULAR/ACR 2018 AND SLICC 2012 HAVE INCREASED SENSITIVITY AGAINST THE ACR 1997 CLASSIFICATION CRITERIA AND CLASSIFY NON-OVERLAPPING GROUPS OF SLE PATIENTS: SIMULTANEOUS APPLICATION ASSURES THE GREATEST CAPTURE OF PATIENTS IN CLINICAL PRACTICE. , 2019, , .		0
72	AB0680"..."NAIFOLD VIDEOCAPILLAROSCOPY PATTERN CORRELATES WITH ORGAN INVOLVEMENT AND DISEASE OUTCOME IN SYSTEMIC SCLEROSIS: A SINGLE-CENTER OBSERVATIONAL STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	FRI0193â€¦2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
74	SAT0240â€¦DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÄ†ETâ€™S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .		0
75	THU0284â€¦WHAT DO HEMATOLOGICAL ABNORMALITIES TELL US IN SLE? RESULTS FROM TWO INDEPENDENT MULTICENTER EUROPEAN SLE COHORTS. , 2019, , .		0
76	OPO277â€¦RNA SEQUENCING AND MACHINE LEARNING TECHNIQUES PREDICT MAJOR ORGAN INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
77	SAT0161â€¦SUSTAINED MODERATE DISEASE ACTIVITY (SMDA) IN RHEUMATOID ARTHRITIS PATIENTS ON BIOLOGIC THERAPIES IS ASSOCIATED WITH 5 YEARS FUNCTIONAL LIMITATION AND SERIOUS ADVERSE EVENTSDEVELOPMENT; EVIDENCE TO SUPPORT TREAT-TO-TARGET APPROACH FOR PATIENTS IN SMDA AND ESPECIALLY THOSE IN HIGH SMDA. , 2019, , .		0
78	AB0678â€¦ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .		0
79	FRI0192â€¦A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
80	SAT0154â€¦STABILIZATION OF RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASEBY RITUXIMAB: A SINGLE CENTER EXPERIENCE WITH LONG-TERM FOLLOW-UP. , 2019, , .		0
81	FRI0411â€¦COMPARABLE CLINICAL RESPONSES BUT HIGHER TREATMENT ADHERENCE OF SECUKINUMAB COMPARED TO TNF INHIBITORS IN SPONDYLOARTHRITIS PATIENTS: LONG TERM PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY HOSPITAL OF GREECE. , 2019, , .		0
82	Machine Learning Classification of Neuropsychiatric Systemic Lupus Erythematosus patients using resting-state fMRI functional connectivity. , 2019, , .		8
83	Cytokine targets in lupus nephritis: Current and future prospects. <i>Clinical Immunology</i> , 2019, 206, 42-52.	3.2	18
84	REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 238-248.	0.9	153
85	Is systemic lupus erythematosus different in urban versus rural living environment? Data from the Cretan Lupus Epidemiology and Surveillance Registry. <i>Lupus</i> , 2019, 28, 104-113.	1.6	10
86	Sexual dimorphism in SLE: above and beyond sex hormones. <i>Lupus</i> , 2019, 28, 3-10.	1.6	48
87	Response to: 'â€™Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadaki<i>et al' </i>by Wallace. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e6-e6.	0.9	1
88	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 696-697.	3.4	2
89	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. <i>Mediterranean Journal of Rheumatology</i> , 2019, 31, 87.	0.8	2
90	Low disease activityâ€™irrespective of serologic status at baselineâ€™associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 467-474.	3.4	59

#	ARTICLE	IF	CITATIONS
91	O003â€¦Characterising the role of net-derived IL-33 in SLE pathogenesis. , 2018, , .		0
92	Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 441-448.	0.9	43
93	P009â€¦Transcriptomic analysis of plasmacytoid dendritic cells from rheumatoid arthritis patients reveals novel targets for therapy. , 2018, , .		0
94	P108â€¦Exploring the molecular basis of gender bias in systemic lupus erythematosus (SLE). , 2018, , .		0
95	P016â€¦Baseline levels of IL-17-producing CD4+ T cells predict clinical response to abatacept in rheumatoid arthritis patients. , 2018, , .		0
96	Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. <i>Rheumatology</i> , 2018, 57, 1494-1495.	1.9	26
97	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Metaâ€Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018, 70, 428-438.	3.4	129
98	Adaptation to inflammatory rheumatic disease: Do illness representations predict patientsâ€™ physical functioning over time? A complex relationship. <i>Journal of Behavioral Medicine</i> , 2018, 41, 232-242.	2.1	4
99	S4D:7â€¦Next generation sequencing in hematopoietic progenitors of murine sle model reveals aberrant regulation of cebp/a expression. , 2018, , .		0
100	S3D:7â€¦Cerebral hypoperfusion detected by perfusion-weighted mri may assist the diagnosis of primary diffuse neuropsychiatric lupus erythematosus. , 2018, , .		0
101	Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 188-205.	3.3	85
102	IFNÎ± Impairs Autophagic Degradation of mtDNA Promoting Autoreactivity of SLE Monocytes in a STING-Dependent Fashion. <i>Cell Reports</i> , 2018, 25, 921-933.e5.	6.4	97
103	2008â€“2018: a decade of recommendations for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1547-1548.	0.9	9
104	PS2:38â€¦Comparative tissue transcriptome analysis by next-generation sequencing reveals novel pathways that characterise genetic susceptibility and developmental biology in systemic lupus erythematosus (sle). , 2018, , .		2
105	Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. <i>Frontiers in Medicine</i> , 2018, 5, 161.	2.6	42
106	New respiratory symptoms and lung imaging findings in a woman with polymyositis. <i>Breathe</i> , 2018, 14, e34-e39.	1.3	0
107	AB0503â€¦Therapeutic strategy and short-term outcome in neuropsychiatric systemic lupus erythematosus. , 2018, , .		0
108	THU0072â€¦Gene signature of plasmacytoid dendritic cells reveals novel pathways contributing to tolerance in rheumatoid arthritis patients. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
109	Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus. Mediterranean Journal of Rheumatology, 2018, 29, 232-235.	0.8	0
110	Patient and partner dispositional optimism as a long-term predictor of illness representations in autoimmune diseases. Journal of Health Psychology, 2017, 22, 1691-1700.	2.3	1
111	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
112	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2017, 76, 476-485.	0.9	590
113	03.23â€¦Transcriptomic analysis of plasmacytoid dendritic cells from rheumatoid arthritis patients reveals novel targets for therapy. , 2017, , .		0
114	08.31â€¦Unravelling the role of il33/st2l axis on sustained ifn-a production in systemic lupus erythematosus. , 2017, , .		0
115	Validity of the Italian algorithm for the attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study. BMJ Open, 2017, 7, e015546.	1.9	35
116	OP0332â€¦The genomic architecture of systemic lupus erythematosus (SLE) by RNA-SEQ: distinct disease susceptibility, activity and severity signatures and extensive genetic effects on whole blood gene expression. , 2017, , .		0
117	THU0254â€¦Comparison of urban versus rural environment associated systemic lupus erythematosus (SLE): risk and clinical features. , 2017, , .		0
118	Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Annals of the Rheumatic Diseases, 2017, 76, 1992-2000.	0.9	68
119	SAT0204â€¦Abatacept survival in rheumatoid arthritis patients at 2 years is 59%; its use as a 2nd line biologic agent and lower baseline haq predict better survival in clinical practice: a prospective, observational single center study. , 2017, , .		0
120	THU0246â€¦The impact of classifying SLE patients with the SLICC-2012 versus the ACR-1997 classification criteria on early diagnosis, severity, and damage: data from the community-based cretan lupus registry. , 2017, , .		0
121	FRI0244â€¦Low dose of rituximab is effective for maintenance of clinical remission or low disease activity in patients with rheumatoid arthritis. , 2017, , .		0
122	AB0442â€¦Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort. , 2017, , .		0
123	05.14â€¦Rna-seq profiling of hematopoietic stem cells in murine systemic lupus erythematosus (sle): validation and functional characterisation. , 2017, , .		0
124	SAT0330â€¦Lower prevalence but comparable clinical characteristics and prognosis of systemic sclerosis in crete-greece as compared to other european countries: a single center experience. , 2017, , .		0
125	FRI0236â€¦After discontinuation of the 1st tumor necrosis factor inhibitor (TNFI), non-tnfi biologic agents have similar responses but higher survival compared to a 2nd course of a different tnfi: long-term prospective observational study of patients with rheumatoid arthritis in a tertiary hospital of greece. , 2017, , .		0
126	Treatment of Systemic Lupus Erythematosus. , 2017, , 1368-1388.e5.		3



#	ARTICLE	IF	CITATIONS
127	Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. <i>Mediterranean Journal of Rheumatology</i> , 2017, 28, 4-12.	0.8	54
128	Cytotoxic-Immunosuppressive Drug Treatment. , 2016, , 533-541.		2
129	Elimination of Granulocytic Myeloid-Derived Suppressor Cells in Lupus-Prone Mice Linked to Reactive Oxygen Species-Dependent Extracellular Trap Formation. <i>Arthritis and Rheumatology</i> , 2016, 68, 449-461.	5.6	44
130	A6.08-...Transcriptome profiling by next generation sequencing of hematopoietic progenitors in murine systemic lupus erythematosus (SLE). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A50.1-A50.	0.9	0
131	Clinical and financial burden of active lupus in Greece: a nationwide study. <i>Lupus</i> , 2016, 25, 1385-1394.	1.6	22
132	Cognitive deficits early in the course of rheumatoid arthritis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 820-829.	1.3	23
133	Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation. <i>European Journal of Immunology</i> , 2016, 46, 2542-2554.	2.9	75
134	FRI0316-...Assessing Attribution of Neuropsychiatric Events in Systemic Lupus Erythematosus. Performance of A New Algorithm in An International Multicenter Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 549.2-550.	0.9	0
135	Vaccination against Human Papillomavirus in relation to Financial Crisis: The "Evaluation and Education of Greek Female Adolescents on Human Papillomaviruses"™ Prevention Strategies"™ELEFThERIA Study. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2016, 29, 362-366.	0.7	15
136	Micro-RNA analysis of renal biopsies in human lupus nephritis demonstrates up-regulated miR-422a driving reduction of kallikrein-related peptidase 4. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1676-1686.	0.7	22
137	Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. <i>Lupus</i> , 2016, 25, 627-636.	1.6	45
138	Adaptation to an autoimmune disorder: Does mental flexibility impact illness-related self-regulation?. <i>Psychology and Health</i> , 2016, 31, 276-291.	2.2	6
139	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.7	97
140	A1.23-...IFN± mediated deregulation of mitochondrial DNA clearance as an inciting event for the development of SLE autoimmunity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A10.1-A10.	0.9	0
141	Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 910-917.	0.8	24
142	AB1119-...The Cretan Lupus Registry "Leto" Prevalence, Clinical Features and Environmental Factors in a Genetically Homogenous, Mixed Urban and Rural, South European Population. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1275.1-1275.	0.9	0
143	SAT0415-...Performance of Anti-Nuclear Antibodies (ANA) for Classifying Systemic Lupus Erythematosus (SLE): A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 809.2-810.	0.9	4
144	AB0175-...Elimination of Granulocytic Myeloid-Derived Suppressor Cells in Lupus-Prone Mice Due to Ros-Dependent Extracellular Trap Formation. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 949.1-949.	0.9	0

#	ARTICLE	IF	CITATIONS
145	A1.32â€¦The role of hematopoietic stem cells (HSC) in systemic autoimmunity. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A14.1-A14.	0.9	0
146	FR10401â€¦Clinical and Financial Burden of SLE in Greece: A Nation-Wide, Multi-Centre Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 571.3-572.	0.9	0
147	A2.23â€¦Deregulated, IFNA driven autophagy shapes the phenotype of autoreactive SLE monocytes. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A25.1-A25.	0.9	0
148	Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 257.	3.5	125
149	Treat-to-target in lupus: what does the future hold?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 461-477.	0.3	4
150	OPO092â€¦Remission in Sle: Consensus Findings from a Large International Panel on Definitions of Remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 103.2-103.	0.9	1
151	EULAR recommendations for neuropsychiatric systemic lupus erythematosus<i>vs</i>usual care: results from two European centres. <i>Rheumatology</i> , 2015, 54, 1270-1278.	1.9	48
152	Dysregulated production of interleukin-1 <sup>2</sup> upon activation of the NLRP3 inflammasome in patients with familial Mediterranean fever. <i>Human Immunology</i> , 2015, 76, 488-495.	2.4	11
153	OPO086â€¦Eular Recommendations for Women's Health and the Management of Family Planning, Assisted Reproduction, Pregnancy, and Menopause in Patients With Systemic Lupus Erythematosus and/or the Antiphospholipid Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 101.1-101.	0.9	2
154	A6.34â€¦The role of the costimulatory receptor herpes virus entry mediator (HVEM) in B-cell activation and differentiation. implications for SLE pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A69.3-A70.	0.9	1
155	Almost Half of Octogenarians and Nonagenarians Admitted Acutely to Internal Medicine Ward Die During Admission or Within 6Months After Discharge: Time to Redefine Treatment Goals?. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 380-383.	2.6	2
156	OPO283â€¦Increased Neutrophil Extracellular TRAP Formation in Rheumatoid Arthritis is Correlated with the Induction of Pathogenic Th1 And/Or TH17 Cell Responses. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 169.1-169.	0.9	0
157	Coexistence of systemic lupus erythematosus and multiple sclerosis: Prevalence, clinical characteristics, and natural history. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 751-758.	3.4	26
158	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
159	Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 447-457.	3.4	80
160	Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant Tâ€¦lymphoproliferative disorders: brief review. <i>Hematological Oncology</i> , 2014, 32, 113-119.	1.7	21
161	THU0367â€¦Familial Mediterranean Fever (FMF): A Single Center Clinical-Genetic Study: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 309.2-309.	0.9	2
162	Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. <i>Nature Genetics</i> , 2013, 45, 202-207.	21.4	483

#	ARTICLE	IF	CITATIONS
163	Diagnostic criteria for systemic lupus erythematosus: has the time come?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 687-694.	8.0	103
164	OP0064â€¦Joint EULAR/ERA-EDTA recommendations for the management of adult and pediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 74.3-75.	0.9	2
165	SAT0006â€¦MicroRNA analysis of human lupus nephritis: Evidence for modulation of kallikrein 4 by MIR-422A. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 472.3-473.	0.9	1
166	An update on the management of comorbid conditions in lupus nephritis. <i>Clinical Investigation</i> , 2013, 3, 281-293.	0.0	0
167	A5.26â€¦Regulation of Expression and Function of Negative Immunomodulatory Receptors in B-Cells: Implications for the Pathogenesis of Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A40.1-A40.	0.9	0
168	Pathogenesis and treatment of CNS lupus. <i>Current Opinion in Rheumatology</i> , 2013, 25, 577-583.	4.3	49
169	Gene expression and regulation in systemic lupus erythematosus. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1084-1096.	3.4	52
170	AB0371â€¦State of the art for treating-to-target in sle: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A900.4-A901.	0.9	0
171	AB0380â€¦Treat-to-target in systemic lupus erythematosus: report from the t2t/sle working party. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A903.2-A903.	0.9	3
172	A2.8â€¦Enhanced Neutrophil Extracellular Trap Formation in Rheumatoid Arthritis Patients is Correlated with High Levels of Rheumatoid Factor (RF). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A7.1-A7.	0.9	0
173	Treatment of Systemic Lupus Erythematosus. , 2013, , 1304-1330.e6.		1
174	Identification of a novel microRNA-gene circuit in human lupus nephritis: evidence for modulation of kallikrein genes by MIR-422A. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A51.1-A51.	0.9	1
175	Regulation of T cell hyperactivity in SLE: the negative co-stimulatory molecule PD-1 regulates miR-21 expression in SLE T lymphocytes. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A58.1-A58.	0.9	0
176	Joint European League Against Rheumatism and European Renal Associationâ€œEuropean Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
177	Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. <i>Arthritis Research and Therapy</i> , 2012, 14, R141.	3.5	145
178	Infections in patients with traumatic brain injury who undergo neurosurgery. <i>British Journal of Neurosurgery</i> , 2011, 25, 9-15.	0.8	27
179	Genetic association and functional consequences of a common SNP in the CD40 region with systemic lupus erythematosus and rheumatoid arthritis in a homogeneous Greek population. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A14-A14.	0.9	1
180	Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1496-1506.	0.9	276

#	ARTICLE	IF	CITATIONS
181	Cyclophosphamide and Lupus Nephritis: When, How, For How Long?. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 181-191.	6.5	14
182	A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2184-2190.	0.9	53
183	Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 437-451.	3.1	3
184	Lupus nephritisâ€”winning a few battles but not the war. <i>Nature Reviews Rheumatology</i> , 2011, 7, 441-442.	8.0	15
185	The programmed death 1/programmed death ligand 1 inhibitory pathway is upâ€regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1870-1880.	6.7	126
186	Gene Network Analysis of Bone Marrow Mononuclear Cells Reveals Activation of Multiple Kinase Pathways in Human Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2010, 5, e13351.	2.5	33
187	Micro RNA analysis reveals novel genes in human systemic lupus erythematosus: miR-21 affects PDCD4 expression and regulates aberrant T cell responses. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A28-A28.	0.9	0
188	A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2059-2061.	0.9	14
189	Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1603-1611.	0.9	121
190	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2074-2082.	0.9	578
191	Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. <i>Nature Reviews Rheumatology</i> , 2010, 6, 358-367.	8.0	218
192	The Effect of Periodic Vegetarianism on Serum Retinol and Î±-tocopherol Levels. <i>International Journal for Vitamin and Nutrition Research</i> , 2009, 79, 271-280.	1.5	26
193	Whatâ€™s new in clinical trials in lupus?. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 473-485.	0.3	2
194	Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2144-2150.	0.7	16
195	Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. <i>Lupus</i> , 2009, 18, 831-835.	1.6	62
196	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 477-483.	0.9	30
197	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 470-476.	0.9	36
198	Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 207-218.	6.7	99

#	ARTICLE	IF	CITATIONS
199	Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. <i>Arthritis Research and Therapy</i> , 2009, 11, R131.	3.5	103
200	Metabolic syndrome in children and adolescents in Crete, Greece, and association with diet quality and physical fitness. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2008, 16, 421-428.	1.6	22
201	Gene expression in systemic lupus erythematosus: Bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. <i>Arthritis and Rheumatism</i> , 2008, 58, 3541-3549.	6.7	61
202	Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future – the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. <i>Lupus</i> , 2008, 17, 437-442.	1.6	56
203	Pharmacotherapy of lupus nephritis: time for a consensus?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2099-2115.	1.8	3
204	EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 195-205.	0.9	645
205	Update on the management of lupus nephritis: let the treatment fit the patient. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 464-472.	3.2	38
206	Toll like receptors and autoimmunity: A critical appraisal. <i>Journal of Autoimmunity</i> , 2007, 29, 310-318.	6.5	101
207	Dietary and other lifestyle correlates of serum folate concentrations in a healthy adult population in Crete, Greece: a cross-sectional study. <i>Nutrition Journal</i> , 2006, 5, 5.	3.4	47
208	Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: Implications for the induction and maintenance of the autoimmune process. <i>Arthritis and Rheumatism</i> , 2006, 54, 3601-3611.	6.7	170
209	Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 28-33.	0.9	129
210	Fruit and Vegetables Consumption in Relation to Health and Diet of Medical Students in Crete, Greece. <i>International Journal for Vitamin and Nutrition Research</i> , 2005, 75, 107-117.	1.5	28
211	Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 22-30.	3.2	25
212	Consumption of Ready-to-Eat Cereals in Relation to Health and Diet Indicators among School Adolescents in Crete, Greece. <i>Annals of Nutrition and Metabolism</i> , 2005, 49, 165-172.	1.9	35
213	Title is missing!. <i>Arthritis Research</i> , 2005, 7, P144.	2.0	0
214	Title is missing!. <i>Arthritis Research</i> , 2005, 7, P153.	2.0	0
215	Nutrient intake and food consumption among medical students in Greece assessed during a Clinical Nutrition course. <i>International Journal of Food Sciences and Nutrition</i> , 2004, 55, 17-26.	2.8	27
216	Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 144-148.	0.9	48

#	ARTICLE	IF	CITATIONS
217	Hair analysis differentiates chronic from acute carbamazepine intoxication. <i>Pediatric Neurology</i> , 2004, 31, 73-75.	2.1	11
218	Review of clinical and toxicological features of acute pesticide poisonings in Crete (Greece) during the period 1991-2001. <i>Medical Science Monitor</i> , 2004, 10, CR622-7.	1.1	12
219	Overweight and obesity in relation to cardiovascular disease risk factors among medical students in Crete, Greece. <i>BMC Public Health</i> , 2003, 3, 3.	2.9	121
220	Cigarette smoking, alcohol consumption, and serum lipid profile among medical students in Greece. <i>European Journal of Public Health</i> , 2003, 13, 278-282.	0.3	57
221	The relation of partners' illness representations to the coping behaviors of patients with inflammatory rheumatic diseases through patients' illness representation: A dyadic regulation process. <i>Current Psychology</i> , 0, , 1.	2.8	0